Indivior initiates Phase 2 study for INDV-2000, targeting opioid use disorder with non-opioid treatment

Indivior PLC (LSE/Nasdaq: INDV) has announced the commencement of a Phase 2 clinical trial involving INDV-2000, a non-opioid treatment, marking a significant advancement in the ... Read More